SP41

SP41 is a synthetic peptide therapeutic being developed by Serpin Pharma for the treatment of severe skin diseases. It is part of a pipeline of peptides derived from the anti-inflammatory and immune-modulating protein Alpha-1 Antitrypsin (AAT). SP41 is designed to leverage the body's natural pro-resolving pathways to treat inflammatory and autoimmune conditions. While specific details on its molecular structure are proprietary, it belongs to a class of peptides developed by Serpin Pharma that typically target the Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) to resolve inflammation without causing broad immunosuppression. The drug is currently in Phase 1 clinical development.